This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
The mineralocorticoid receptor antagonist did not reduce primary outcomes in the CLEAR SYNERGY trial, but there was a suggestion that it did prevent new or worsening heart failure.
Medscape Medical News